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ABSTRACT
Mutations due to hereditary-related genes such as BRCA1, BRCA2, TP53 and 
PTEN confer greater risk of developing breast cancer. BRCA mutations were also 
found to be related to ovarian cancer. The risk assessment based on genetic 
testing allows options of surveillance and prevention in high-risk patients, as well 
as guiding physicians in selecting specific treatment, such as targeted therapies 
and platinum base chemotherapy. Once an individual has been found to carry 
the BRCA mutation, the choice of management might also vary. Moreover, the 
availability of genetic testing and other novel methods of testing, such as the 
Next Generation Sequencing techniques, have also provided options for clinicians.
Breast Surgeons are most likely to be the first person encountering patients at 
their first presentation. It is important for breast surgeons to be actively involved 
in the referrals of high-risk patients for genetic testing, and subsequently in the 
planning of therapy, in a multidisciplinary setting. Basic principles of genetic 
testing and choice of management would be discussed in reference to the 
surgeon’s perspectives.
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